RecruitingPhase 2NCT06488313

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

A Phase 2a, Open-label, Multiple Ascending Dose Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency

Sponsor

Arcturus Therapeutics, Inc.

Enrollment

9 participants

Start Date

Nov 4, 2024

Study Type

INTERVENTIONAL

Conditions

Ornithine Transcarbamylase Deficiency OTC Deficiency OTCD

Summary

Evaluate the safety and pharmacodynamics of multiple doses of ARCT-810 in adolescent and adult participants with OTC deficiency.

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called ARCT-810 for people with otc deficiency, otcd, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALARCT-810

ARCT-810 is an investigational medicinal product comprising Ornithine Transcarbamylase (OTC) messenger RNA (mRNA) formulated in a lipid nanoparticle (LNP).